PHARMACYCLICS, INC.

Inactief instrument

Koers Pharmacyclics, Inc.

Aandelen

US7169331060

Biotechnologie & Medisch Onderzoek

slotkoers Nasdaq Andere beurzen
- ^USD	-

Nieuws in andere talen over Pharmacyclics, Inc.

Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	07-01-16
Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	07-01-16
Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	07-01-16
Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	07-01-16
Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	07-01-16

Managers en directeuren - Pharmacyclics, Inc.

Managers	Titel	Leeftijd	Van
Wulff-Erik von Borcke CEO	Chief Executive Officer	-	01-05-15
Betty Chang CTO	Chief Tech/Sci/R&D Officer	-	09-07-13
Heow Tan CTO	Chief Tech/Sci/R&D Officer	65	01-05-12

Bedrijfsprofiel

Sector

Biotechnologie & Medisch Onderzoek

Meer informatie over het bedrijf

Sector Biotechnologie & Medisch Onderzoek - Andere

	Vaira. 1 jan.	Kapi.
IQVIA HOLDINGS INC.	+1,51%	42,75 mld.
LONZA GROUP AG	+49,22%	41,61 mld.
MODERNA, INC.	+8,57%	41,34 mld.
CELLTRION, INC.	-12,36%	26,59 mld.
ICON PUBLIC LIMITED COMPANY	+8,92%	25,49 mld.
ALNYLAM PHARMACEUTICALS, INC.	-25,13%	18,12 mld.
MEDPACE HOLDINGS, INC.	+29,17%	12,24 mld.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3,12%	11,76 mld.
UNITED THERAPEUTICS CORPORATION	+6,35%	11 mld.

Biotechnologie & Medisch Onderzoek - Andere

Alle transcripties over 9000 bedrijven, de dag van publicatie!

Krijg nu toegang!

fermer